NCT02006745View on ClinicalTrials.gov

Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
HIV
Interventions
DRUG

Ribavirin

24 weeks in those achieving RVR (undetectable HCV RNA at 4 weeks) or 48 weeks in those not achieving RVR

DRUG

Telaprevir

12 weeks in those achieving RVR, 24 weeks in those not achieving RVR (HCV RNA \>25 but \<1000 iU/mL at week 4) or 48 weeks in those not achieving RVR (HCV RNA \>1000 iU/mL at week 4).

Trial Locations (1)

SW10 9TH

St Stephens AIDS Trust, London

All Listed Sponsors
lead

St Stephens Aids Trust

OTHER

NCT02006745 - Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT) | Biotech Hunter | Biotech Hunter